Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians
Authors Foster A, Wang Z, Usman M, Stirewalt E, Buckley P
Published 15 January 2008 Volume 2007:3(6) Pages 965—973
Adriana Foster1, Zixuan Wang2, Manzoor Usman1, Edna Stirewalt1, Peter Buckley1
1Department of Psychiatry and Health Behavior and 2Department of Medicine and Pathology, Medical College of Georgia, Augusta, GA, USA
Abstract: There is a growing body of literature supporting the contribution of genetic variability to the mechanisms responsible for the adverse effects of antipsychotic medications particularly movement disorders and weight gain. Despite the current gap between research studies and the practical tools available to the clinician to identify such risks, it is hoped that in the foreseeable future, pharmacogenetics will become a critical aid to guide the development of personalized therapeutic regimes with fewer adverse effects. We provide a summary of two cases that are examples of using cytochrome P450 pharmacogenetics in an attempt to guide treatment in the context of recent literature concerning the role of pharmacogenetics in the manifestation of adverse effects of antipsychotic therapies. These examples and the review of recent literature on pharmacogenetics of antipsychotic adverse effects illustrate the potential for applying the principles of predictive, preventive, and personalized medicine to the therapy of psychotic disorders.
Keywords: pharmacogenetics, adverse effects, antipsychotic drugs
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]